Last reviewed · How we verify

PYZCHIVA (USTEKINUMAB-TTWE)

SAMSUNG BIOEPIS CO LTD · FDA-approved approved Quality 6/100

PYZCHIVA (generic name: USTEKINUMAB-TTWE) is a Interleukin-12 Antagonist [EPC] drug developed by SAMSUNG BIOEPIS CO LTD. It is currently FDA-approved.

At a glance

Generic nameUSTEKINUMAB-TTWE
SponsorSAMSUNG BIOEPIS CO LTD
Drug classInterleukin-12 Antagonist [EPC]
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

Serious adverse events

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about PYZCHIVA

What is PYZCHIVA?

PYZCHIVA (USTEKINUMAB-TTWE) is a Interleukin-12 Antagonist [EPC] drug developed by SAMSUNG BIOEPIS CO LTD.

Who makes PYZCHIVA?

PYZCHIVA is developed and marketed by SAMSUNG BIOEPIS CO LTD (see full SAMSUNG BIOEPIS CO LTD pipeline at /company/samsung-bioepis).

What is the generic name of PYZCHIVA?

USTEKINUMAB-TTWE is the generic (nonproprietary) name of PYZCHIVA.

What drug class is PYZCHIVA in?

PYZCHIVA belongs to the Interleukin-12 Antagonist [EPC] class. See all Interleukin-12 Antagonist [EPC] drugs at /class/interleukin-12-antagonist-epc.

What development phase is PYZCHIVA in?

PYZCHIVA is FDA-approved (marketed).

What are the side effects of PYZCHIVA?

Common side effects of PYZCHIVA include Infections, Malignancies (excluding non-melanoma skin cancer), Non-melanoma skin cancer. Serious adverse events: Serious infections, Serious infections (placebo-controlled period), Posterior Reversible Encephalopathy Syndrome (PRES), Cellulitis.

Related